Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients


Creative Commons License

Kanbay M., Siriopol D., Saglam M., Kurt Y. G. , Gok M., Cetinkaya H., ...More

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol.99, no.10, 2014 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Article
  • Volume: 99 Issue: 10
  • Publication Date: 2014
  • Doi Number: 10.1210/jc.2014-2042
  • Journal Name: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
  • Journal Indexes: Science Citation Index Expanded, Scopus

Abstract

Background: The chronic kidney disease (CKD)-mineral and bone disorder (MBD) syndrome is an important contributor to the CKD-associated cardiovascular disease and high mortality rates. Sclerostin, a protein synthesized in osteocytes, is a potent downregulator of bone metabolism and a novel candidate for the bone-vascular axis in CKD patients. We tested whether serum sclerostin values are predictive for all-cause mortality and cardiovascular events (CVEs) in a CKD population.